Dr. Weber on the Updated Analysis of the CheckMate-238 Trial in Melanoma

Video

Jeffrey S. Weber, MD, PhD, discusses the updated analysis of the phase III CheckMate-238 trial in patients with resected stage III/IV melanoma.

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program, NYU Langone’s Perlmutter Cancer Center, 2016 Giant of Cancer Care in Melanoma, discusses the updated analysis of the phase III CheckMate-238 trial in patients with resected stage III/IV melanoma.

Initials results of the trial demonstrated an improvement in relapse-free survival (RFS) with nivolumab (Opdivo) versus ipilimumab (Yervoy) in patients with resected stage III/IV melanoma. The efficacy of nivolumab was maintained at 24 months of follow-up. At 36 months of follow-up, nivolumab showed a sustained benefit in RFS that compared favorably to what was seen with ipilimumab (HR, 0.68; P&thinsp;<0.0001), says Weber. In addition to RFS, updated distant metastasis-free survival data similarly demonstrated an improvement with nivolumab versus ipilimumab (HR, 0.78; P = .044).

At 3 years, the RFS rates were 58% in the nivolumab arm and 45% in the ipilimumab arm. Moreover, interferon-gamma gene expression signature, tumor mutational burden, and CD8+ T-cell infiltration were associated with an improvement in RFS for nivolumab and ipilimumab.

<<< View more from the 2019 ESMO Congress

Related Videos
Patrick I. Borgen, MD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Reshma Lillaney Mahtani, DO
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center